The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schauer, S. L.
Right arrow Articles by Sonenshein, G. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schauer, S. L.
Right arrow Articles by Sonenshein, G. E.
The Journal of Immunology, 1998, 160: 4398-4405.
Copyright © 1998 by The American Association of Immunologists

Dominant Signals Leading to Inhibitor {kappa}B Protein Degradation Mediate CD40 Ligand Rescue of WEHI 231 Immature B Cells from Receptor-Mediated Apoptosis1

Stephanie L. Schauer2,*, Robert E. Bellas{dagger} and Gail E. Sonenshein3,{dagger}

Departments of * Microbiology and {dagger} Biochemistry, Boston University Medical School, Boston, MA 02118

Recently, we demonstrated maintenance of nuclear factor (NF)-{kappa}B/Rel factors plays a major role in B cell survival. Treatment of WEHI 231 immature B cells with an Ab against the surface IgM protein (anti-IgM) induces apoptosis that can be rescued by engagement of CD40 receptor. The dramatic decrease in high basal levels of NF-{kappa}B/Rel activity induced by anti-IgM treatment led to cell death. CD40 ligand (CD40L) treatment prevented the drop in NF-{kappa}B/Rel factor binding by inducing a sustained decrease in inhibitor (I) {kappa}B-{alpha} and transient decrease in I{kappa}B-ß protein levels. In this study, we have investigated the regulation of these NF-{kappa}B/Rel-inhibitory proteins. In exponentially growing WEHI 231 cells, the I{kappa}B-{alpha} and I{kappa}B-ß proteins decayed with an approximate t1/2 of 38 and 76 min, respectively, which was blocked effectively upon addition of the proteasome-specific inhibitor (benzylcarbonyl)-Leu-Leu-phenylalaninal (Z-LLF-CHO). Anti-IgM treatment stabilized I{kappa}B-{alpha} and I{kappa}B-ß proteins. CD40L treatment resulted in a dramatic decrease in t1/2 (<5 min) for both I{kappa}B molecules, which was inhibited by addition of Z-LLF-CHO. CD40L treatment also caused a delayed increase in I{kappa}B-ß mRNA levels, most likely contributing to the observed recovery of I{kappa}B-ß levels. Microinjection of I{kappa}B-{alpha}-glutathione S-transferase fusion protein into nuclei of WEHI 231 cells ablated protection by CD40L from receptor-mediated killing. Furthermore, CD40L rescued apoptosis induced upon microinjection of a vector expressing wild-type I{kappa}B-{alpha}, but not a 32A/36A mutant form of I{kappa}B-{alpha}, unable to be phosphorylated and hence degraded. Thus, control of turnover of I{kappa}B proteins by CD40L plays a major role in maintenance of NF-{kappa}B/Rel and resultant rescue of WEHI 231 cells from apoptosis.




This article has been cited by other articles:


Home page
J. Immunol.Home page
S. Doerre, K. P. Mesires, K. M. Daley, T. McCarty, S. Knoetig, and R. B. Corley
Reductions in I{kappa}B{epsilon} and Changes in NF-{kappa}B Activity during B Lymphocyte Differentiation
J. Immunol., January 15, 2005; 174(2): 983 - 991.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. Guilbault and R. J. Kay
RasGRP1 Sensitizes an Immature B Cell Line to Antigen Receptor-induced Apoptosis
J. Biol. Chem., May 7, 2004; 279(19): 19523 - 19530.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
F. Zazzeroni, S. Papa, A. Algeciras-Schimnich, K. Alvarez, T. Melis, C. Bubici, N. Majewski, N. Hay, E. De Smaele, M. E. Peter, et al.
Gadd45{beta} mediates the protective effects of CD40 costimulation against Fas-induced apoptosis
Blood, November 1, 2003; 102(9): 3270 - 3279.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
W. J. M. Mackus, S. M. A. Lens, R. H. Medema, M. J. Kwakkenbos, L. M. Evers, M. H. J. v. Oers, R. A. W. v. Lier, and E. Eldering
Prevention of B cell antigen receptor-induced apoptosis by ligation of CD40 occurs downstream of cell cycle regulation
Int. Immunol., September 1, 2002; 14(9): 973 - 982.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. D. Shumway, C. M. Berchtold, M. N. Gould, and S. Miyamoto
Evidence for Unique Calmodulin-Dependent Nuclear Factor-kappa B Regulation in WEHI-231 B Cells
Mol. Pharmacol., January 1, 2002; 61(1): 177 - 185.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Shen, P. Channavajhala, D. C. Seldin, and G. E. Sonenshein
Phosphorylation by the Protein Kinase CK2 Promotes Calpain-Mediated Degradation of I{kappa}B{alpha}
J. Immunol., November 1, 2001; 167(9): 4919 - 4925.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. R. Fields, B. J. Seufzer, E. M. Oltz, and S. Miyamoto
A Switch in Distinct I{kappa}B{alpha} Degradation Mechanisms Mediates Constitutive NF-{kappa}B Activation in Mature B Cells
J. Immunol., May 1, 2000; 164(9): 4762 - 4767.
[Abstract] [Full Text] [PDF]


Home page
Cell Growth Differ.Home page
D. Donjerkovic, L. Zhang, and D. W. Scott
Regulation of p27Kip1 Accumulation in Murine B-Lymphoma Cells: Role of c-Myc and Calcium
Cell Growth Differ., October 1, 1999; 10(10): 695 - 704.
[Abstract] [Full Text]


Home page
J. Immunol.Home page
S. Doerre and R. B. Corley
Constitutive Nuclear Translocation of NF-{kappa}B in B Cells in the Absence of I{kappa}B Degradation
J. Immunol., July 1, 1999; 163(1): 269 - 277.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Patil, G. M. Wildey, T. L. Brown, L. Choy, R. Derynck, and P. H. Howe
Smad7 Is Induced by CD40 and Protects WEHI 231 B-lymphocytes from Transforming Growth Factor-beta -induced Growth Inhibition and Apoptosis
J. Biol. Chem., December 1, 2000; 275(49): 38363 - 38370.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1998 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1998 by The American Association of Immunologists, Inc. All rights reserved.